The biopharmaceutical services company Clean Cells, specialized in biosafety testing and cell bank and virus seed stock production, has reached an agreement with ArchiMed to invest in the Company and become its new majority shareholder.
Over the past three years, Clean Cells has experienced substantial growth in its original core business segments and made a successful launch as CDMO in the phage therapy sector. ArchiMed has joined the capital of Clean Cells to help drive the Company’s growth strategy in its core business areas and to strengthen its investment capacity. ArchiMed is buying out family members and other long-standing shareholders, including T.O.D. Finances and Sodero Gestion, that have supported the three founders over the past 15 years.
ArchiMed is the first independent, Pan-European private equity group focused on healthcare SMEs. The group is continuing to invest in the biopharmaceutical production and development field, following its investments in Deallus Consulting, Polyplus-transfection and Provepharm Life Solutions. ArchiMed and two of the founders of Clean Cells are joining forces to roll out an ambitious strategy to strengthen the Company’s market position in biosafety testing and cell and virus seed banking at an international level, and to develop the phage therapy CDMO activity. A new pharmaceutical production site will be operational in 2020 to address the growing number of projects.
Clean Cells has become an important player in the biopharmaceutical sector thanks to its staff of 80 employees. Through its growth project focused on the Human dimension, the Company will continue to develop the quality of its work environment to promote personal development, to strengthen competencies and to stimulate the emergence of new talents, thereby ensuring the sustained quality of its specialist services for the benefit of its customers. These values of collective success and development are shared by ArchiMed.
The ArchiMed team brings its strong experience of the bioproduction value chain, which will further strengthen the current expertise within Clean Cells.